About Baebies
Baebies is a company based in Durham (United States) founded in 2013 by Richard West and Vamsee Pamula. Baebies has raised $95.89 million across 29 funding rounds from investors including Duke University, HHS and CARB-X. Baebies offers products and services including FINDER Platform and G6PD Test. Baebies operates in a competitive market with competitors including Vgenomics and DNADVENTLifesciences, among others.
- Headquarter Durham, United States
- Founders Richard West, Vamsee Pamula
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Baebies Diagnostics India Private Limited
- Date of Incorporation 18 Jan, 2023
- Jurisdiction Serilingampally, Telangana, India
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$95.89 M (USD)
in 29 rounds
-
Latest Funding Round
$2.05 M (USD), Series C
Sep 04, 2025
-
Investors
Duke University
& 8 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Baebies
Baebies offers a comprehensive portfolio of products and services, including FINDER Platform and G6PD Test.
Multifunctional system for rapid medical tests using digital microfluidics.
Assesses G6PD deficiency for clinical interventions on the platform.
People of Baebies
Unlock access to complete
Unlock access to complete
Funding Insights of Baebies
Baebies has successfully raised a total of $95.89M across 29 strategic funding rounds. The most recent funding activity was a Series C round of $2.05 million completed in September 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Baebies
Baebies has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Duke University, HHS and CARB-X.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Angel investments are made in Charleston-based companies by member network.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Baebies
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Baebies
Investment portfolio details for Baebies
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Baebies
Detailed financials for Baebies
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Baebies Comparisons
Peer comparison for Baebies
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Baebies
Baebies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Vgenomics and DNADVENTLifesciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Diagnostic and therapeutic solutions for inborn diseases are developed.
|
|
| Locked | Locked | Locked |
Offers comprehensive genomic-based diagnostic tests for newborn babies.
|
Detailed competitors of Baebies
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Baebies
Complete news archive for Baebies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Baebies
Baebies was founded in 2013.
Baebies is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
Richard West is the current CEO of Baebies. They have also founded this company.
Baebies is a funded company, having raised a total of $95.89M across 29 funding rounds to date.
Provider of diagnostic products for pediatrics. Its proprietary platform the SEEKER is a microfluidic instrument that enables the high-throughput measurement of enzymatic activity in dried blood specimens of newborn babies. It also has another product the FINDER which is an automated screening solution for critical pediatric tests.
Baebies's top competitors include Vgenomics and DNADVENTLifesciences.
Baebies offers FINDER Platform and G6PD Test.
Baebies has 9 investors. Key investors include Duke University, HHS, CARB-X, BOE Technology Group, and NCBiotech.